Skip to main content
. Author manuscript; available in PMC: 2013 Jan 10.
Published in final edited form as: Nature. 2011 Mar 24;471(7339):523–526. doi: 10.1038/nature09870

Figure 1. Mutant EGFR oncogene dependence requires downregulation of the FAS-NF-κB pathway.

Figure 1

a, Viability (CellTiter-Glo assay) of H1650 cells treated with vehicle or 100 nM erlotinib upon introduction of either a non-target siRNA pool or gene-specific siRNA pools targeting the genes. Relative cell viability is fold change in viability in erlotinib relative to vehicle non-target siRNA control (viability decrease >25% = validated). n = 3; mean + s.e.m. b, Caspase 3/7 activation (Caspase-Glo assay) in indicated cell lines treated as in a. c, d, Viability (CellTiter-Glo assay) of indicated isogenic HBEC cells treated as in a. n = 3; mean + s.e.m.